16. Oktober 2020

Epigenomics AG: Staatliche US-Krankenversicherung Centers for Medicare & Medicaid Services veröffentlichen negativen NCD-Erstattungsvorschlag für Epi proColon

Epigenomics AG / Schlagwort(e): Sonstiges
Epigenomics AG: Staatliche US-Krankenversicherung Centers for Medicare & Medicaid Services veröffentlichen negativen NCD-Erstattungsvorschlag für Epi proColon

17.10.2020 / 00:03 CET/CEST
Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch DGAP – ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Staatliche US-Krankenversicherung Centers for Medicare & Medicaid Services veröffentlichen negativen NCD-Erstattungsvorschlag für Epi proColon

Berlin, 16. Oktober 2020 – Die Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; das „Unternehmen“) gibt bekannt, dass die staatliche US-amerikanische Krankenversicherung Centers for Medicare & Medicaid Services (CMS) einen negativen Erstattungsvorschlag im Zusammenhang mit der National Coverage Determination (NCD) von Epi proColon, dem von Epigenomics entwickelten Bluttest zur Darmkrebsvorsorge, veröffentlicht haben.

Diese Entscheidung ist vorläufig. Nach den Statuten der CMS startet nun eine 30-tägige öffentliche Kommentierungsphase, die dazu genutzt werden wird, die CMS erneut von den Vorteilen von Epi proColon im Kampf gegen Darmkrebs zu überzeugen. Die Reaktion der Öffentlichkeit während der ersten öffentlichen Kommentierungsphase zu Beginn der NCD fiel in überwältigendem Maß positiv aus. Im Anschluss an die Kommentierungsphase werden die CMS innerhalb von 60 Tagen ihre endgültige Entscheidung veröffentlichen. Sollte die endgültige Entscheidung ebenfalls negativ ausfallen, wird die Gesellschaft die Möglichkeit nutzen, die Entscheidung über ein Berufungsverfahren anzufechten.

Kontakt:
Unternehmen
Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: ir@epigenomics.com

Hinweis zu zukunftsgerichteten Aussagen

Diese Veröffentlichung enthält ausdrücklich oder implizit in die Zukunft gerichtete Aussagen, die die Epigenomics AG und deren Geschäftstätigkeit betreffen. Diese Aussagen beinhalten bestimmte bekannte und unbekannte Risiken, Unsicherheiten und andere Faktoren, die dazu führen können, dass die tatsächlichen Ergebnisse, die Finanzlage und die Leistungen der Epigenomics AG wesentlich von den erwarteten Ergebnissen oder Leistungen abweichen, die in solchen Aussagen explizit oder implizit zum Ausdruck gebracht wurden. Epigenomics macht diese Mitteilung zum Datum der heutigen Veröffentlichung und beabsichtigt nicht, die hierin enthaltenen, in die Zukunft gerichteten Aussagen aufgrund neuer Informationen oder künftiger Ereignisse bzw. aus anderweitigen Gründen zu aktualisieren.

17.10.2020 CET/CEST Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de

Sprache:	Deutsch
Unternehmen:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Deutschland
Telefon:	+49 30 24345-0
Fax:	+49 30 24345-555
E-Mail:	ir@epigenomics.com
Internet:	www.epigenomics.com
ISIN:	DE000A11QW50
WKN:	A11QW5
Börsen:	Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart, Tradegate Exchange
EQS News ID:	1141448


Ende der Mitteilung	DGAP News-Service

13. Oktober 2020

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG
13.10.2020 / 15:35
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Epigenomics AG
Geneststraße 5
10829 Berlin Deutschland

12th October 2020

Notification pursuant to Sec. 43 of the German Securities Trading Act

Dear Sirs,

Referring to the voting rights notification dated 29/09/2020 notifying that Morgan Stanley, Wilmington, Delaware, USA, has exceeded the threshold of 10% of the voting rights in Epigenomics AG on 25/09/2020, we hereby make the following notification pursuant to Sec. 43 of the German Securities Trading Act (Wertpapierhandelsgesetz):

1. The increase of voting rights resulting in Morgan Stanley exceeding the notification threshold of 10% of the voting rights in Epigenomics AG did not serve the purpose of strategic goals; rather it was made in the context of client facilitation.

2. Morgan Stanley may in the next 12 months acquire further voting rights in Epigenomics AG, in particular in the context of client facilitation.

3. Morgan Stanley does not intend to influence the composition of the management board, supervisory board or any other administrative body of Epigenomics AG.

4. Morgan Stanley does not intend to cause a significant change in the capital structure of Epigenomics AG, in particular not of the ratio between equity and debt financing and the dividend policy.

5. The increase of voting rights resulting in Morgan Stanley exceeding the notification threshold of 10% of the voting rights in Epigenomics AG resulted from and/or was made in the context of client facilitation. The increase was financed by a combination of external and Morgan Stanley own funds.

Yours sincerely,

_

Craig Horsley, Executive Director
Regulatory Operations
Morgan Stanley

13.10.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

30. September 2020

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG
30.09.2020 / 12:13
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
X	Other reason: Notification is triggered due to the non application of the Custody Exemption available under Sect. 36 Para. 3 No. 2 WpHG

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

Morgan Stanley & Co. LLC

5. Date on which threshold was crossed or reached:

25 Sep 2020

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	11.60 %	0.03 %	11.64 %	47129846
Previous notification	7.56 %	0.02 %	7.58 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	5468086	0.00 %	11.60 %
Total	5468086		11.60 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	15838	0.03 %
		Total	15838	0.03 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	11.60 %	%	11.62 %
–	%	%	%
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	%	%	%
Prime Dealer Services Corp.	%	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

29 Sep 2020

30.09.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

25. September 2020

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG
25.09.2020 / 17:13
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Epigenomics AG
Geneststraße 5
10829 Berlin
Deutschland

Notification pursuant to Sec. 43 of the German Securities Trading Act

25th September 2020

Dear Sirs,

Referring to the voting rights notification dated 02/09/2020 notifying that Morgan Stanley, Wilmington, Delaware, USA, has exceeded the threshold of 10% of the voting rights in Epigenomics AG, we hereby make the following notification pursuant to Sec. 43 of the German Securities Trading Act (Wertpapierhandelsgesetz):

1. The acquisition of voting rights resulting in Morgan Stanley exceeding the notification threshold of 10% of the voting rights in Epigenomics AG did not serve the purpose of strategic goals; rather it was made in the context of client facilitation.

2. Morgan Stanley may in the next 12 months acquire further voting rights in Epigenomics AG, in particular in the context of client facilitation.

3. Morgan Stanley does not intend to influence the composition of the management board, supervisory board or any other administrative body of Epigenomics AG.

4. Morgan Stanley does not intend to cause a significant change in the capital structure of of Epigenomics AG, in particular not of the ratio between equity and debt financing and the dividend policy.

5. The acquisition of voting rights resulting in Morgan Stanley exceeding the notification threshold of 10% of the voting rights in Epigenomics AG resulted from and/or was made in the context of client facilitation. The acquisition was financed by a combination of external and Morgan Stanley own funds.

25.09.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

25. September 2020

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG
25.09.2020 / 17:09
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
X	Other reason: Notification is triggered due to the application of the Custody Exemption available under Sect. 36 Para. 3 No. 2 WpHG

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

Morgan Stanley & Co. LLC

5. Date on which threshold was crossed or reached:

21 Sep 2020

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	7.56 %	0.02 %	7.58 %	47129846
Previous notification	11.52 %	0.02 %	11.53 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	3563649	0.00 %	7.56 %
Total	3563649		7.56 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	7919	0.02 %
		Total	7919	0.02 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	7.56 %	%	7.58 %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

25 Sep 2020

25.09.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

23. September 2020

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG
23.09.2020 / 08:36
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Epigenomics AG
Geneststraße 5
10829 Berlin
Deutschland

Notification pursuant to Sec. 43 of the German Securities Trading Act

22nd September 2020

Dear Sirs,

Referring to the voting rights notification dated 16/09/2020 notifying that Morgan Stanley, Wilmington, Delaware, USA, has exceeded the threshold of 10% of the voting rights in Epigenomics AG, we hereby make the following notification pursuant to Sec. 43 of the German Securities Trading Act (Wertpapierhandelsgesetz):

1. The acquisition of voting rights resulting in Morgan Stanley exceeding the notification threshold of 10% of the voting rights in Epigenomics AG did not serve the purpose of strategic goals; rather it was made in the context of client facilitation.

2. Morgan Stanley may in the next 12 months acquire further voting rights in Epigenomics AG, in particular in the context of client facilitation.

3. Morgan Stanley does not intend to influence the composition of the management board, supervisory board or any other administrative body of Epigenomics AG.

4. Morgan Stanley does not intend to cause a significant change in the capital structure of Epigenomics AG, in particular not of the ratio between equity and debt financing and the dividend policy.

5. The acquisition of voting rights resulting in Morgan Stanley exceeding the notification threshold of 10% of the voting rights in Epigenomics AG resulted from and/or was made in the context of client facilitation. The acquisition was financed by a combination of external and Morgan Stanley own funds.

23.09.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

News & Investoren

Archive

Epigenomics AG: Staatliche US-Krankenversicherung Centers for Medicare & Medicaid Services veröffentlichen negativen NCD-Erstattungsvorschlag für Epi proColon

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Archiv

News-Kategorien

Medienkontakt